.png){kind=icon}
返回
M
Masaki Mandai
kyoto university
56H指数
687论文数
1.8W被引数
收录论文 137
发表时间
.png){kind=icon}
.png){kind=icon}
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia日本PMDA关于抗肿瘤药物使用注意事项的审批与修订更新；encorafenib用于结直肠癌，daratumumab用于多发性骨髓瘤，repotrectinib用于NTRK融合阳性实体瘤，以及venetoclax用于白血病。.png)
OAAI
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma日本PMDA关于抗癌药物使用注意事项的审批与修订监管更新；肺癌的durvalumab、cemiplimab、zongertinib和taletrectinib，淋巴瘤的pirtobrutinib和atezolizumab，膀胱癌的durvalumab，结直肠癌的panitumumab联合sotorasib，以及胶质瘤的vorasidenib。
PREAI
分享收藏PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma日本PMDA关于抗肿瘤药物使用注意事项的批准与修订监管更新；nivolumab联合ipilimumab用于结直肠癌，trastuzumab deruxtecan用于乳腺癌，以及acalabrutinib用于套细胞淋巴瘤。
PREAI
分享收藏PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma日本PMDA关于抗癌药物使用注意事项的审批与修订监管更新；nivolumab联合ipilimumab用于肝细胞癌，fedratinib用于骨髓纤维化，talquetamab用于多发性骨髓瘤，以及belzutifan用于与von Hippel-Lindau病和肾细胞癌相关的肿瘤
PREAI
分享收藏